Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | KLK7 | P49862 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067181 | 1.00 | SMYD2 (0.39) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL30683282 | 1.00 | SMYD2 (0.39) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL26618886 | 0.89 | SMYD2 (0.40) | SMYD2 | |
| SCHEMBL6481524 | 0.88 | SMYD2 (0.40) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL31526761 | 0.86 | SMYD2 (0.37) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL31526819 | 0.86 | SMYD2 (0.37) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL16584658 | 0.85 | SMYD2 (0.38) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL16584659 | 0.85 | SMYD2 (0.38) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL9914215 | 0.84 | SMYD2 (0.38) | SMYD2KLK7GPR119KLK5STS | |
| SCHEMBL12091005 | 0.84 | SMYD2 (0.38) | SMYD2KLK7GPR119KLK5STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| EP-0809624-B1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | BEARSDEN BIO INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-5731348-A | NERVOUS SYSTEM DISORDERS | BEARSDEN BIO, INC. (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | SLC18A2, SLC1A2, SLC1A1 | SMYD2 2812/4885KLK7 3884/4885GPR119 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.